Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market leader. Girin goes on to explain the high key growth strategy he is implementing and the impact that BALT’s products can have on the quickly developing medical field of stroke treatment.
The number one problem of BALT today is meeting market demands. Our products have very unique features and I truly believe they are the best on the market in terms of quality and technology
